Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CTIC CTI BioPharma (CTIC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About CTI BioPharma Stock (NASDAQ:CTIC) 30 days 90 days 365 days Advanced Chart Ad The Bull ReportAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With demand for electricity skyrocketing from data centers, AI, and emerging tech, Amazon recognizes nuclear power as the only viable solution to meet its needs sustainably and at scale. But here's the critical catch: nuclear power requires uranium, and the global supply is struggling to keep up. Read More to Learn How You Can Position Yourself for the Next Uranium Boom Get CTI BioPharma alerts:Sign Up Key Stats Today's Range$9.09▼$9.0950-Day Range$8.91▼$9.1052-Week Range$4.01▼$9.10VolumeN/AAverage Volume4.50 million shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.Read More… Amazon's $150B Data Center Bet—What It Means for Uranium Investors (Ad)Amazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With demand for electricity skyrocketing from data centers, AI, and emerging tech, Amazon recognizes nuclear power as the only viable solution to meet its needs sustainably and at scale. But here's the critical catch: nuclear power requires uranium, and the global supply is struggling to keep up. Read More to Learn How You Can Position Yourself for the Next Uranium Boom Receive CTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CTIC Stock News HeadlinesLineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ...October 9, 2024 | gurufocus.comQ2 2024 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptAugust 17, 2024 | gurufocus.comAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With demand for electricity skyrocketing from data centers, AI, and emerging tech, Amazon recognizes nuclear power as the only viable solution to meet its needs sustainably and at scale. But here's the critical catch: nuclear power requires uranium, and the global supply is struggling to keep up. November 12, 2024 | The Bull Report (Ad)Brainstorm Cell Therapeutics Inc (BCLI) Q2 2024 Earnings Call Transcript Highlights: ...August 17, 2024 | gurufocus.comQ1 2024 Veracyte Inc Earnings CallMay 8, 2024 | uk.finance.yahoo.comConnect Biopharma Holdings Ltd (CNTB)February 22, 2024 | investing.comTheravance Biopharma Inc TBPHDecember 16, 2023 | morningstar.comCTI Engineering Co Ltd (9621)October 23, 2023 | uk.investing.comSee More Headlines CTIC Stock Analysis - Frequently Asked Questions How were CTI BioPharma's earnings last quarter? CTI BioPharma Corp. (NASDAQ:CTIC) announced its quarterly earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biopharmaceutical company had revenue of $21.08 million for the quarter, compared to analyst estimates of $24.88 million. When did CTI BioPharma's stock split? Shares of CTI BioPharma reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of CTI BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Advanced Micro Devices (AMD) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings3/06/2023Today11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTIC Previous SymbolNASDAQ:CTICD CUSIPN/A CIK891293 Webwww.ctibiopharma.com Phone(206) 282-7100Fax206-284-6206Employees127Year Founded1992Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,990,000.00 Net Margins-91.38% Pretax Margin-91.38% Return on EquityN/A Return on Assets-55.82% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.26 Sales & Book Value Annual Sales$53 million Price / Sales22.62 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-64.93Miscellaneous Outstanding Shares131,880,000Free Float121,844,000Market Cap$1.20 billion OptionableOptionable Beta0.83 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:CTIC) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersWith a $2B neighbor nearby, this underfollowed lithium explorer could have the next big strike!This Lithium Company Scoops Up the Largest Continuous Land Package in Brazil’s Lithium Boom Positioning the Co...Huge Alerts | SponsoredAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredOptions Trading on Bitcoin?SEC Approves Crypto Options Trading Select altcoins poised for RAPID growth by early 2025… Crypto 101 Media | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CTI BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share CTI BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
